Publication | Closed Access

621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

Dose-escalation StudyMedicineImmunologyAdvanced Solid TumorsFibroblast Growth FactorCancer TreatmentOncologyRadiation OncologyCancer ResearchCancer Growth